BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23531772)

  • 21. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
    Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
    Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma.
    Parisella M; D'Alessandria C; van de Bossche B; Chianelli M; Ronga G; Papini E; Mikolajczak R; Letizia C; De Toma G; Veneziani A; Scopinaro F; Signore A
    Cancer Biother Radiopharm; 2004 Apr; 19(2):211-7. PubMed ID: 15186602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.
    Agrawal K; Patro PSS; Preetam C
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
    Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
    Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
    Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.
    Vukomanovic VR; Matovic M; Doknic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Peulic M; Djukic A
    Nucl Med Commun; 2019 Jan; 40(1):41-51. PubMed ID: 30334858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
    Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
    Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
    Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
    Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.
    Jing H; Li F; Zhuang H; Wang Z; Tian J; Xing X; Jin J; Zhong D; Zhang J
    Eur J Radiol; 2013 Nov; 82(11):2028-34. PubMed ID: 23721625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.